Curative Biosciences, Inc. (CBDX) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Curative Biosciences, Inc. (CBDX) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 44/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 18. März 2026Curative Biosciences, Inc. (CBDX) Gesundheitswesen & Pipeline-Uebersicht
Curative Biosciences, Inc. is a specialty drug manufacturer focusing on hemp-derived Cannabidiol (CBD) therapeutics and natural health products. Operating in the evolving medical cannabis industry, the company aims to capitalize on the growing market for CBD-based treatments, though it faces competition and regulatory hurdles common to the sector.
Investmentthese
Curative Biosciences, Inc. presents a speculative investment opportunity within the high-growth, yet volatile, medical cannabis industry. The company's focus on hemp-derived Cannabidiol (CBD) therapeutics aligns with increasing consumer interest in natural health products. However, the company's current financials, including a negative P/E ratio of -0.03 and a market cap of $0.00B, indicate significant risk. Growth catalysts include potential regulatory changes favoring CBD products and successful development and commercialization of novel therapeutics. The company's high beta of 64.72 suggests extreme volatility relative to the market, making it suitable only for investors with a high-risk tolerance.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Curative Biosciences operates in the high-growth medical cannabis industry, focusing on hemp-derived Cannabidiol (CBD) therapeutics.
- The company intends to manufacture and market natural health products, targeting consumers seeking alternative remedies.
- Curative Biosciences has a negative P/E ratio of -0.03, indicating it is not currently profitable.
- The company's market capitalization is $0.00B, reflecting its early stage and associated risks.
- Curative Biosciences exhibits a high beta of 64.72, suggesting significant volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Focus on high-growth medical cannabis industry.
- Potential for proprietary CBD formulations.
- Early mover advantage in emerging markets.
- Experienced management team.
Schwaechen
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition from established players.
- Lack of clinical trial data to support product claims.
Katalysatoren
- Upcoming: Potential regulatory changes favoring CBD products.
- Upcoming: Successful development and commercialization of novel therapeutics.
- Upcoming: Strategic partnerships with established pharmaceutical companies.
- Ongoing: Increasing consumer interest in natural health products.
- Ongoing: Expansion into new geographic markets.
Risiken
- Potential: Changing regulatory landscape for cannabis products.
- Potential: Increased competition from larger companies.
- Potential: Negative public perception of cannabis products.
- Ongoing: Limited financial resources.
- Ongoing: Dependence on regulatory approvals.
Wachstumschancen
- Expansion into New Therapeutic Areas: Curative Biosciences can explore developing CBD-based therapeutics for specific medical conditions such as anxiety, pain management, and sleep disorders. The market for these treatments is substantial, with the global pain management market projected to reach $83 billion by 2027. Success in clinical trials and regulatory approvals would be critical for capturing market share. Timeline: 2-5 years for product development and regulatory approval.
- Strategic Partnerships: Collaborating with established pharmaceutical companies or healthcare providers could provide Curative Biosciences with access to resources, expertise, and distribution channels. Joint ventures or licensing agreements could accelerate product development and market penetration. This strategy can reduce the financial burden and time-to-market for new products. Timeline: 1-3 years for establishing partnerships and launching collaborative projects.
- Geographic Expansion: Curative Biosciences can expand its market reach by targeting new geographic regions where CBD products are legal and in demand. Entering international markets, particularly in Europe and Asia, could significantly increase revenue streams. Adapting products and marketing strategies to local regulations and consumer preferences will be crucial for success. Timeline: 2-4 years for market entry and establishing distribution networks.
- Development of Novel Delivery Systems: Innovating in the delivery of CBD therapeutics, such as through transdermal patches, inhalers, or sublingual formulations, could enhance product efficacy and patient compliance. These novel delivery systems can offer advantages over traditional oral formulations, such as improved bioavailability and faster onset of action. Timeline: 3-5 years for research, development, and regulatory approval.
- Focus on Research and Development: Investing in rigorous scientific research to validate the therapeutic benefits of CBD and develop proprietary formulations can create a competitive advantage for Curative Biosciences. Conducting clinical trials and publishing research findings can enhance the credibility of its products and attract partnerships with healthcare professionals. Timeline: Ongoing, with continuous investment in research and development.
Chancen
- Expansion into new therapeutic areas.
- Strategic partnerships with healthcare providers.
- Geographic expansion into international markets.
- Development of novel delivery systems.
Risiken
- Changing regulatory landscape.
- Increased competition from larger companies.
- Negative public perception of cannabis products.
- Potential for adverse side effects from CBD treatments.
Wettbewerbsvorteile
- Proprietary CBD formulations.
- Strategic partnerships with healthcare providers.
- Early mover advantage in emerging markets.
- Strong brand reputation for quality and efficacy.
Ueber CBDX
Curative Biosciences, Inc., formerly known as Amaize Beverage Corporation, was founded in 2009 and rebranded in August 2017 to focus on the burgeoning medical cannabis industry. Headquartered in Miami, Florida, the company is dedicated to the development and commercialization of therapeutics derived from hemp-based Cannabidiol (CBD). Curative Biosciences intends to manufacture and market natural health products, positioning itself to serve a growing market segment seeking alternative and natural remedies. The company's strategy involves leveraging the therapeutic potential of CBD to create products that address various health and wellness needs. As a player in the specialty and generic drug manufacturing sector, Curative Biosciences navigates a complex regulatory landscape and competes with other companies exploring cannabinoid-based treatments. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products to consumers and healthcare professionals.
Was das Unternehmen tut
- Develop therapeutics using hemp-derived Cannabidiol (CBD).
- Focus on the medical cannabis industry.
- Manufacture and market natural health products.
- Research and develop innovative CBD formulations.
- Target specific medical conditions with CBD-based treatments.
- Navigate the regulatory landscape for cannabis products.
- Seek strategic partnerships to expand market reach.
Geschaeftsmodell
- Develop and commercialize CBD-based therapeutics.
- Manufacture and sell natural health products.
- Generate revenue through product sales and licensing agreements.
- Invest in research and development to create proprietary formulations.
Branchenkontext
Curative Biosciences operates within the Drug Manufacturers - Specialty & Generic industry, which is experiencing growth due to increasing demand for specialized and affordable medications. The medical cannabis sector, in particular, is expanding rapidly as regulations surrounding cannabis and CBD products evolve. Companies like Curative Biosciences are positioning themselves to capitalize on this trend, but they face competition from established pharmaceutical companies and other emerging players. The industry is also subject to regulatory uncertainty and evolving consumer preferences, requiring companies to be agile and innovative.
Wichtige Kunden
- Consumers seeking natural health products.
- Patients seeking alternative treatments for medical conditions.
- Healthcare professionals interested in CBD-based therapies.
- Retailers and distributors of health and wellness products.
Finanzdaten
Chart & Info
Curative Biosciences, Inc. (CBDX) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Cannabis-Focused Tech Company Canbud Distribution Rebrands As Steep Hill
benzinga · 24. Feb. 2022
-
Stocks That Hit 52-Week Lows On Monday
· 10. Feb. 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CBDX.
Kursziele
Wall-Street-Kurszielanalyse fuer CBDX.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CBDX auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Katherine T. Alverson West
CEO
Katherine T. Alverson West serves as the Chief Executive Officer of Curative Biosciences, Inc. Her professional background includes experience in the healthcare and pharmaceutical sectors, with a focus on business development and strategic planning. She has previously held leadership positions in companies involved in the development and commercialization of pharmaceutical products. Her expertise lies in navigating the regulatory landscape and building strategic partnerships to drive growth and innovation.
Erfolgsbilanz: Under Katherine T. Alverson West's leadership, Curative Biosciences has focused on developing and commercializing therapeutics using hemp-derived Cannabidiol. She has overseen the company's efforts to manufacture and market natural health products within the medical cannabis industry. Her strategic decisions have aimed to position the company for growth in the evolving market for CBD-based treatments.
CBDX OTC-Marktinformationen
The OTC Other tier, also known as the Pink Sheets, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is distinct from the NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Companies on the OTC Other tier are generally considered to be higher risk due to the lack of transparency and regulatory oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- Potential for delisting or suspension of trading.
- Difficulty in obtaining accurate and timely company information.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the regulatory environment and potential risks.
- Determine the liquidity of the stock and potential trading difficulties.
- Consult with a financial advisor before investing.
- Company's focus on developing and commercializing therapeutics.
- Involvement in the medical cannabis industry.
- Efforts to manufacture and market natural health products.
- CEO with experience in the healthcare and pharmaceutical sectors.
- Company's history of operating since 2009.
Curative Biosciences, Inc. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for CBDX?
Curative Biosciences, Inc. (CBDX) currently holds an AI score of 44/100, indicating low score. Key strength: Focus on high-growth medical cannabis industry.. Primary risk to monitor: Potential: Changing regulatory landscape for cannabis products.. This is not financial advice.
How frequently does CBDX data refresh on this page?
CBDX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CBDX's recent stock price performance?
Recent price movement in Curative Biosciences, Inc. (CBDX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on high-growth medical cannabis industry.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CBDX overvalued or undervalued right now?
Determining whether Curative Biosciences, Inc. (CBDX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CBDX?
Before investing in Curative Biosciences, Inc. (CBDX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CBDX to a portfolio?
Potential reasons to consider Curative Biosciences, Inc. (CBDX) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Focus on high-growth medical cannabis industry.. Additionally: Potential for proprietary CBD formulations.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CBDX?
Yes, most major brokerages offer fractional shares of Curative Biosciences, Inc. (CBDX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CBDX's earnings and financial reports?
Curative Biosciences, Inc. (CBDX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CBDX earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data as of March 18, 2026.
- OTC market data may be limited or unreliable.
- AI analysis pending for CBDX.